Please use this identifier to cite or link to this item: http://hdl.handle.net/10311/2173
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMartei, Yehoda M.-
dc.contributor.authorChiyapo, Sebathu-
dc.contributor.authorRamogola-Masire, Doreen-
dc.contributor.authorDryden-Peterson, Scott M.-
dc.contributor.authorShulman, Lawrence N.-
dc.contributor.authorTapela, Neo-
dc.date.accessioned2021-09-23T12:52:46Z-
dc.date.available2021-09-23T12:52:46Z-
dc.date.issued2018-01-23-
dc.identifier.citationMartei, Yehoda M. et al (2018) Availability of WHO essential medicines for cancer treatment in Botswana. Journal of Global Oncology, Vol. 4, pp. 1-8en_US
dc.identifier.issn2378-9506 (online)-
dc.identifier.urihttp://hdl.handle.net/10311/2173-
dc.description.abstractPurpose Stock outs of cancer drugs are potentially fatal but have not been systematically studied in low- and middle-income countries. The aim of this study was to determine the availability and alignment of the Botswana National Essential Medicines List (NEML) for cancer drugs with the WHO’s Essential Medicines List (EML). Methods The availability and cost of cancer drugs were analyzed using data from a weekly stock catalog sent by Botswana’s Central Medical Store to all pharmacy departments in government hospitals. Comparative data were extracted from the WHO EML and the “International Drug Price Indicator Guide-2014” from the Management Sciences for Health. Interviews with key informants were used to collect data on the Botswana NEML and the drug supply chain in the public sector. Results The 2015 Botswana NEML for cancer had 80.5% alignment with the WHO EML. At least 40% of essential drugs were out of stock for a median duration of 30 days in 2015. Stock outs affected chemotherapy drugs included in first-line regimens for treating potentially curable diseases such as cervical, breast, and colorectal cancer and were not associated with buyer price of therapy. Analyses showed that the median price ratio for procured drugs was greater than 1 for 61% of the NEML drugs, which suggests inefficiency in procurement in the public sector. Conclusions Botswana has one of the highest alignments of NEML to the WHO EML in the sub-Saharan African region, which is consistent with investment in the health care system evident in other clinical spheres. Better quantification of chemotherapy requirements using data from the National Cancer Registry and resource-sensitive treatment guidelines can help reduce stock outs and facilitate more effective and efficient procurement processes.en_US
dc.language.isoenen_US
dc.publisherAmerican Society of Clinical Oncology, http://www.asco.org/en_US
dc.rightsLicensed under the Creative Commons Attribution 4.0 Licenseen_US
dc.subjectCancer treatmenten_US
dc.subjectEssential medicinesen_US
dc.subjectCancer drugsen_US
dc.subjectEssential Medicines List (EML)en_US
dc.subjectWHOen_US
dc.subjectBotswanaen_US
dc.titleAvailability of WHO essential medicines for cancer treatment in Botswanaen_US
dc.typePublished Articleen_US
dc.rights.holderAmerican Society of Clinical Oncologyen_US
dc.linkhttps://doi.org/10.1200/JGO.17.00063en_US
Appears in Collections:Research articles (Dept of Obstetrics & Gynaecology)



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.